174 related articles for article (PubMed ID: 16865312)
1. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year.
Newman ED; Matzko CK; Olenginski TP; Perruquet JL; Harrington TM; Maloney-Saxon G; Culp T; Wood GC
Osteoporos Int; 2006; 17(9):1428-34. PubMed ID: 16865312
[TBL] [Abstract][Full Text] [Related]
2. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
Arthritis Rheumatol; 2017 Aug; 69(8):1521-1537. PubMed ID: 28585373
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
5. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Byun Robinson A; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1095-1110. PubMed ID: 28585410
[TBL] [Abstract][Full Text] [Related]
6. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012.
Albaum JM; Lévesque LE; Gershon AS; Liu G; Cadarette SM
Osteoporos Int; 2015 Dec; 26(12):2845-52. PubMed ID: 26138581
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
[TBL] [Abstract][Full Text] [Related]
10. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
McKeown E; Bykerk VP; De Leon F; Bonner A; Thorne C; Hitchon CA; Boire G; Haraoui B; Ferland DS; Keystone EC; Pope JE;
Rheumatology (Oxford); 2012 Sep; 51(9):1662-9. PubMed ID: 22539481
[TBL] [Abstract][Full Text] [Related]
11. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
12. Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Song BW; Kim AR; Kim MA; Kim HS; Lee SG
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208647
[No Abstract] [Full Text] [Related]
13. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Feldstein AC; Elmer PJ; Nichols GA; Herson M
Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
15. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
[TBL] [Abstract][Full Text] [Related]
16. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
17. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
18. [Glucocorticoid-induced osteoporosis : treatment update].
Soen S
Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
[TBL] [Abstract][Full Text] [Related]
19. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
20. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]